Myeloma UK Chief Executive Blog – July 2018

Find out about what Myeloma UK Chief Executive, Rosemarie Finley, has been getting up to in July.

Myeloma UK news // 27th July 2018

I was delighted to visit Freeman Hospital along with the Myeloma UK Healthcare Professionals team, to present them with the Clinical Services Excellence Programme award.  It was fantastic to present the award to acknowledge the outstanding work of Professor Graham Jackson and his team. We are proud of their commitment to ensuring that myeloma patients receive the best treatment and care at the hospital.

We also received a Highly Commended award for two of our Easy Read publications – How is myeloma treated? and How will myeloma affect me? – in the British Medical Association (BMA) Patient Information Awards 2018. This means that the publications have been shortlisted for the overall BMA Patient Information Award 2018, which will be announced in September. I am thrilled to have our Patient Information Specialists’ hard work recognised by the BMA, joining other Highly Commended Myeloma UK resources, including Kelsey and the Yellow Kite, Planning ahead: An Infopack for myeloma patients and Infopack for carers of myeloma patients.

This month, The National Institute for Health and Care Excellence (NICE) issued a draft “no” on the treatment combination of daratumumab (Darzalex®), bortezomib (Velcade®) and dexamethasone for the treatment of patients with relapsed or refractory myeloma. We are very disappointed with the decision and have been in discussions with both NICE and Janssen to work on next steps. Further information on the decision can be found here.

I would like to thank all of our fundraisers and supporters this month, who helped us to fund vital services and innovative research to help make myeloma history.

Best Wishes

Rosemarie Finley

Chief Executive

Myeloma UK